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A case of intracranial hemorrhage in a neonate with 
congenital factor VII deficiency
Congenital factor VII deficiency is a rare autosomal-recessive bleeding 
disorder. Bleeding manifestations and clinical findings vary widely, 
ranging from asymptomatic subjects to patients with hemorrhages 
that may cause significant handicaps. Treatment has traditionally 
involved factor VII(FVII) replacement therapy using fresh frozen 
plasma, prothrombin complex concentrates or plasma-derived 
FVII concentrates. Recombinant activated FVII (NovoSeven
®) is 
currently considered the first-line treatment for replacement therapy 
of FVII deficiency. Here we present a case of severe intracerebral 
and intraventricular hemorrhage in a neonate with congenital FVII 
deficiency.
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Introduction
Factor VII (FVII) is a vitamin K-dependent clotting factor 
that is part of the extrinsic pathway of blood coagulation
1). The 
complex formed between the naturally occurring procoagulant 
serine protease, activated FVII (FVIIa), and the integral membrane 
protein tissue factor (TF), exposed on the vascular lumen upon 
injury, is known to be the trigger for  blood clotting. In the 
blood stream, FVIIa is the active portion of the FVII mass and is 
detectable at normal concentrations as low as 5-10 ng, i.e., 1-2% of 
the zymogen; in contrast to FVII zymogen, FVIIa has a very high 
affinity for TF
1, 2). 
Congenital FVII deficiency is a rare bleeding disorder. In patients 
with congenital FVII deficiency, bleeding manifestations and 
clinical findings vary widely, ranging from asymptomatic subjects 
to life threatening bleeding
1, 3). However, severe and life-threatening 
hemorrhaging is rare in general (about 5% of the bleeds) and occurs 
most frequently during the first six months of life. The correlation 
between FVII coagulation activity (FVII:C) and bleeding tendency 
appears to be poor
4, 5). Treatment has traditionally involved FVII 
replacement therapy using fresh frozen plasma, prothrombin 
complex concentrates (PCCs) or plasma FVII concentrates
2, 3). 
Intravenous administration of recombinant FVIIa (NovoSeven
®, 
NovoNordisk, Bagsvaerd, Denmark) is now widely used for the 
treatment of FVII deficiency. Here we present a case of severe 
intracerebral and intraventricular hemorrhage in a neonate with 
congenital FVII deficiency.
Case report
A 28-day-old male neonate was referred with fever for five 
days and sudden progress of anemia, suggestive of an intracranial 
hemorrhage (ICH). He was born to a 35-year-old gravida 1, para 
1 mother at 39
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any perinatal problems. His birth weight was 3,000 g. There was 
no significant family history about any bleeding disorder. At the 
time of transfer, the pulse rate was 150 beats/min, respiratory 
rate was 42 breaths/min, blood pressure was 80/50 mmHg and 
body temperature was 37.3℃. Physical examination revealed 
pallor, anemic conjunctivae, and a minimal systolic murmur. The 
head circumference was 38 cm (50-75 percentile) and there were 
no abnormalities on the neurological examination. Laboratory 
findings were as follows: hemoglobin of 6.5 g/dL; white blood cell 
(WBC) count of 17,500/mm
3; and a platelet count of 387,000/
mm
3. CRP was 1.03 mg/dL (normal range: 0.0-0.5). The blood 
coagulation test revealed a prothrombin time 34.8 seconds (INR 
3.65) and activated partial thromboplastin time of 34.2 seconds. 
The FVII assay was 2%. Brain computed tomography (CT) 
demonstrated an intraventricular hemorrhage in both lateral 
ventricles with hydrocephalus and an intracerebral hemorrhage 
in the right parietotemporal lobe and corpus callosum (Fig. 1). 
On admission, recombinant activated FVII (Novoseven
®, Novo 
Nordisk, Bagsvaerd, Denmark) was administrated at a dose of 
20 μ g/kg every 4 hours. To treat the hydrocephalus, external 
ventricular drainage was considered; however, the risk of bleeding 
was a concern. Therefore, periodic lumbar puncture and drainage 
were performed and mannitol was administered. First lumbar 
puncture was done at hospital day 3 and performed every 3-4 days 
after Novoseven® was administrated. Results of CSF study were as 
follows: Red blood cell count of 23,000/mm
3, WBC count of 77/
mm
3; glucose of 18 mg/dL, protein of 223.0 mg/dL. The FVII 
level was checked 1 hr after administration of the Novoseven
® 
and was confirmed to be 125%. The interval between dosing with 
Novoseven
® was increased to seven days after admission. The 
fever persisted until seven days after admission, and then, finally 
subsided. Blood, urine, CSF, and stool culture were unremarkable. 
The patient was treated with a third generation cephalosporin. The 
brain CT at seven days after admission revealed decreased IVH 
in both lateral ventricles and slight resolution of the ICH with 
perilesional edema. Administration of the FVII was continued 
Fig. 1. Brain CT on admission showed an IVH in both lateral ventricles with hydrocephalus 
and ICH with perilesional edema in the right parietotemporal lobe and corpus callosum.
Fig. 2. A follow-up brain CT scan 1 month later revealed a resolving ICH, decreased IVH 
and slightly improved hydrocephalus.Korean J Pediatr 2010;53(10):913-916 • DOI: 10.3345/kjp.2010.53.10.916    915
for 20 days during the hospitalization. The patient was discharged 
21 days after admission. A follow-up CT of the brain at 1 month 
showed a resolving ICH, decreased IVH and slightly improved 
hydrocephalus (Fig. 2). At present, the patient is on no medication 
and is followed in the outpatient clinic regularly. The development 
currently is within normal limits. A follow-up CT scan of the brain 
and developmental testing are planned.
Discussion
Congenital FVII deficiency is a rare autosomal recessive bleeding 
disorder that has an estimated incidence of 1/500,000 among the 
general population
6). There are 20 known patients with congenital 
FVII deficiency in Korea
7). And, neonate with FVII deficiency 
and ICH has not been reported yet. FVII plays a pivotal role in the 
initiation of hemostasis and coagulation. Binding of FVII to TF 
in the damaged vascular bed results in rapid conversion of FVII to 
FVIIa through the action of proteases
1, 8). In turn, FVII plays a key 
role in the early phases of the intrinsic and extrinsic coagulation 
pathways through activation of factor IX (FIX) and factor X (FX).
Nosebleeds are a common symptom. This disorder is not gender-
related. Other very common symptoms are postoperative, skin 
and gum bleeding
1, 2). A female gender is more common among 
bleeders: this is mainly attributable to menorrhagia. Severe and 
life-threatening hemorrhages are rare in general (about 5% of the 
bleeds) and occur most frequently during the first six months of 
life. According to some reports, central nervous system (CNS) 
bleeding has been identified in 4.4-8%. Severe bleeding, CNS and 
gastrointestinal bleeding have been reported mainly in babies and 
infants
1, 3, 5).
In patients with hemophilia A and B, a reliable classification 
of severity can be obtained by plasma factor VIII or IX activity 
levels. Depending on the concentration of FVIII or FIX coagulant 
activity in the blood, the disorders may be classified as severe (<1% 
of normal activity). In patients with FVIII or IX concentrations 
in plasma <1% of normal, joint bleeding episodes may occur as 
frequently as 20-30 times/year, and life-threatening bleeding such 
as intracranial hemorrhage may occur
9). However, in a study on 
FVII deficiency, it was reported that patients with FVII:C levels 
below 2% were either asymptomatic or had a very mild phenotype; 
by contrast, patients with FVII:C levels above 5%, most had   
severe symptoms. Even when FVII:C levels are statistically lower 
in bleeders, it is generally agreed that they do not predict bleeding 
tendency in an  individual patient
5, 10). 
Treatment of congenital FVII deficiency consists of replacement 
therapy with fresh frozen plasma (FFP), PCCs, FVII concentrates 
and/or recombinant FVIIa (NovoSeven
®)
4, 11). As FFP, PCCs and 
FVII concentrates are plasma-derived products, the use of these 
products is associated with the risk of transmission of pathogens
12). 
In addition, the use of PCCs results in an unwanted increase in 
other vitamin-K-dependent factors and is associated with both 
arterial and venous thrombosis. Recombinant FVIIa has been 
available on a compassionate and emergency use basis since 1988 
for patients with hemophilia with inhibitors to FVIII or FIX, 
and patients with congenital FVII deficiency
4, 12). Intravenous 
administration of recombinant FVIIa (NovoSeven
®) is now widely 
used for the treatment of FVII deficiency; however, there are no 
recommended guidelines for the dose and treatment schedule. 
According to recent reports, the median dose per injection (22 μ g/
kg) was within the dose range recommended in the protocols for 
FVII-deficient patients (15-30 μg/kg every 4-6 h until hemostasis 
was achieved). For more severe bleeding (e.g. central nervous system 
and internal bleeding episodes) the patients were treated for a 
longer period of time. Treatment with recombinant FVIIa for CNS 
bleeding was rated as effective in 11/14 cases
4, 11). Cases of ICH with 
FVII deficiency treated by FFP have been reported
13, 14). In the case 
reported here, recombinant FVIIa was administrated at dose of 20 
μ g/kg for 20 days, and it was effective.
Review of the medical literature revealed that as many as one-
third of episodes recorded in the neonatal period had a delayed 
diagnosis and/or treatment
10, 15, 16). Pediatricians should be advised 
of the need for hemostasis control in newborns with ICH. 
This should facilitate the early diagnosis of possible hemophilia 
and appropriate treatment. The frequency and significance of 
neonatal ICH underscores the importance of the early diagnosis 
of hemophilia. Moreover, children should be closely followed for 
several days as symptoms of ICH may be delayed for up to six days 
in the case of severe hemophilia, and longer for mild hemophilia. 
For the case reported here, there were no specific signs of an ICH, 
e.g. persistent vomiting, change of mental status, seizure; the patient 
had the nonspecific findings of fever and poor feeding. The initial 
administration of factor replacement was started five days after the 
fever developed.
Prophylactic therapy with factor concentrates is currently the 
most effective intervention available for the prevention of bleeding 
episodes in patients with hemophilia. In congenital FVII deficiency, 
prophylaxis has been a debated issue, especially because of the very 
brief maintenance of infused FVII in the blood stream
17, 18). One 
report suggests that prophylactic treatment with recombinant 
FVIIa in patients with FVII deficiency with dosage of 20-30 μ g/kg 
once to twice weekly may be beneficial in preventing hemorrhagic 
complications in spite of the short plasma half life
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remains a controversial issue.
In summary, congenital FVII deficiency is a rare inherited 
bleed  ing disorder. Clinical heterogeneity is the hallmark of this 
hemorrhagic disorder; the severity ranges from lethal to mild, and 
there are asymptomatic forms. Here, a case of FVII deficiency and 
severe ICH with successful management using recombinant FVIIa 
is reported.
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